Pharma Mar Sa Stock Market Capitalization
PHM Stock | EUR 75.50 0.10 0.13% |
Pharma Mar SA fundamentals help investors to digest information that contributes to Pharma Mar's financial success or failures. It also enables traders to predict the movement of Pharma Stock. The fundamental analysis module provides a way to measure Pharma Mar's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pharma Mar stock.
Pharma |
Pharma Mar SA Company Market Capitalization Analysis
Pharma Mar's Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Current Pharma Mar Market Capitalization | 1.09 B |
Most of Pharma Mar's fundamental indicators, such as Market Capitalization, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharma Mar SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
Competition |
Based on the recorded statements, the market capitalization of Pharma Mar SA is about 1.09 B. This is 91.61% lower than that of the Healthcare sector and 77.1% lower than that of the Biotechnology industry. The market capitalization for all Spain stocks is 94.3% higher than that of the company.
Pharma Market Capitalization Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pharma Mar's direct or indirect competition against its Market Capitalization to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pharma Mar could also be used in its relative valuation, which is a method of valuing Pharma Mar by comparing valuation metrics of similar companies.Pharma Mar is currently under evaluation in market capitalization category among its peers.
Pharma Fundamentals
Return On Equity | 0.47 | |||
Return On Asset | 0.13 | |||
Profit Margin | 0.35 % | |||
Operating Margin | 0.33 % | |||
Current Valuation | 1.07 B | |||
Shares Outstanding | 18.09 M | |||
Shares Owned By Insiders | 26.95 % | |||
Shares Owned By Institutions | 10.48 % | |||
Price To Earning | (38.29) X | |||
Price To Book | 5.69 X | |||
Price To Sales | 5.17 X | |||
Revenue | 229.83 M | |||
Gross Profit | 213.39 M | |||
EBITDA | 104.08 M | |||
Net Income | 92.86 M | |||
Cash And Equivalents | 42.72 M | |||
Cash Per Share | 0.19 X | |||
Total Debt | 33.39 M | |||
Current Ratio | 0.94 X | |||
Book Value Per Share | 9.88 X | |||
Cash Flow From Operations | 25.68 M | |||
Earnings Per Share | 4.64 X | |||
Target Price | 76.34 | |||
Number Of Employees | 477 | |||
Beta | 0.12 | |||
Market Capitalization | 1.09 B | |||
Total Asset | 368.39 M | |||
Z Score | 19.2 | |||
Annual Yield | 0.01 % | |||
Net Asset | 368.39 M | |||
Last Dividend Paid | 0.65 |
About Pharma Mar Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharma Mar SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharma Mar using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharma Mar SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Pharma Stock
Pharma Mar financial ratios help investors to determine whether Pharma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharma with respect to the benefits of owning Pharma Mar security.